Hexokinase 2 (HK2) catalyses the initial phosphorylation of glucose to sustain glycolytic flux into cancer cells, while its overexpression enhances glycolytic flux, supporting drug resistance and tumour growth besides associated with poor prognosis [14,54,62,63,64,65,66]. This evidence concerns the gene HK2 and neoplasm.